Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.57 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182434 | 0.98 | DDB1 (0.58) | DDB1CRBNGID4NPC1MEN1 | |
| SCHEMBL317559 | 0.94 | GID4 (0.63) | DDB1CRBNGID4NPC1MEN1 | |
| SCHEMBL21286784 | 0.88 | DDB1 (0.67) | DDB1CRBNGID4NPC1MEN1 | |
| SCHEMBL6404794 | 0.85 | SMN1; SMN2 (0.47) | DDB1CRBNGID4RAB9AMAPT | |
| SCHEMBL11534052 | 0.83 | SMN1; SMN2 (0.46) | DDB1CRBNGID4MEN1KMT2A | |
| SCHEMBL10109186 | 0.83 | MAPK1 (0.45) | DDB1CRBNGID4MEN1KMT2A | |
| SCHEMBL318339 | 0.83 | MAPK1 (0.45) | DDB1CRBNGID4MEN1KMT2A | |
| SCHEMBL11873333 | 0.81 | MAPK1 (0.55) | DDB1CRBNNPC1MEN1KMT2A | |
| SCHEMBL21452545 | 0.80 | ADCYAP1R1 (0.47) | DDB1CRBNGID4 | |
| SCHEMBL318066 | 0.80 | MAPK1 (0.56) | DDB1CRBNNPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436005-B2 | Macrocyclic pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2013-05-07 | — | — | US | disclosed |
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| EP-1010689-B1 | Substituted cycloheptenes, their preparation and use | GRUENENTHAL GMBH (DE) | 2003-01-15 | — | — | EP | disclosed |
| US-6323369-B1 | AS ANALGESICS | GRUENENTHAL GMBH (DE) | 2001-11-27 | — | — | US | disclosed |
| EP-1010689-A1 | Substituted cycloheptenes, their preparation and use | Grünenthal GmbH (DE) | 2000-06-21 | — | — | EP | disclosed |
| US-4219652-A | N-Methyl and N-phenethyl-cis-decahydroisoquinolines | ELI LILLY AND COMPANY (US) | 1980-08-26 | — | — | US | disclosed |
| US-4100166-A | Novel cis N-cyclopropylmethyl decahydroisoquinoline | ELI LILLY AND COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | DDB1 219/4885CRBN 2408/4885GID4 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.